Skip to main content
Erschienen in: CME 12/2020

16.12.2020 | Opioide | CME Fortbildung

Neue Therapieoptionen in der Substitutionsbehandlung

Opiatabhängigkeit

verfasst von: Prof. Dr. Michael Soyka

Erschienen in: CME | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Substitutionstherapie mit langwirksamen Opioiden hat eine herausragende Bedeutung für die Behandlung und Versorgung von Menschen mit Opiatabhängigkeit. Das Spektrum der einsetzbaren Substanzen hat sich in der letzten Zeit deutlich erweitert, wodurch sich die Prognose für Opiatabhängige erheblich verbessert hat.
Literatur
1.
Zurück zum Zitat Busch M, Anzenberger J, Uhl A. Mortalität von Menschen mit Opiatabhängigkeit. Suchtmedizin 2019;21:967-372 Busch M, Anzenberger J, Uhl A. Mortalität von Menschen mit Opiatabhängigkeit. Suchtmedizin 2019;21:967-372
2.
Zurück zum Zitat Degenhardt L et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014;109(8):1320-33 Degenhardt L et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014;109(8):1320-33
3.
Zurück zum Zitat Walter M, Soyka M. Opioide. In: Soyka M et al. (Hrsg). Suchtmedizin. München: Elsevier, 2019:177-202 Walter M, Soyka M. Opioide. In: Soyka M et al. (Hrsg). Suchtmedizin. München: Elsevier, 2019:177-202
4.
Zurück zum Zitat Schuckit MA. Treatment of opioid-use disorders. N Engl J Med 2016;375:1596-7 Schuckit MA. Treatment of opioid-use disorders. N Engl J Med 2016;375:1596-7
5.
Zurück zum Zitat Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-Assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6 Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-Assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6
6.
Zurück zum Zitat Atzendorf Jm Rauschert L, Seitz NN, Lochbühler K, Kraus L. Gebrauch von Alkohol, Tabak, illegalen Drogen und Medikamenten. Dtsch Ärzteblatt 2019;116:577-84 Atzendorf Jm Rauschert L, Seitz NN, Lochbühler K, Kraus L. Gebrauch von Alkohol, Tabak, illegalen Drogen und Medikamenten. Dtsch Ärzteblatt 2019;116:577-84
7.
Zurück zum Zitat Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht 2019: Trends und Entwicklungen, Amt für Veröffentlichungen der Europäischen Union, Luxemburg Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht 2019: Trends und Entwicklungen, Amt für Veröffentlichungen der Europäischen Union, Luxemburg
8.
Zurück zum Zitat Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;10:CD004147 Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;10:CD004147
9.
Zurück zum Zitat Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol 2014;77:253-63 Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol 2014;77:253-63
10.
Zurück zum Zitat Bell J, Strang J. Medication Treatment of opioid use disorder. Biol Psychiatry 2019; in Press Doi.10.10.16/j.biopsych.2019.06.020 Bell J, Strang J. Medication Treatment of opioid use disorder. Biol Psychiatry 2019; in Press Doi.10.10.16/j.biopsych.2019.06.020
11.
Zurück zum Zitat Mattick RP, Breen C. Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207. doi: 10.1002/14651858.CD002207.pub4. PubMed PMID: 24500948 Mattick RP, Breen C. Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207. doi: 10.1002/14651858.CD002207.pub4. PubMed PMID: 24500948
12.
Zurück zum Zitat Bundesärztekammer (2017) Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger. URL: Bundesärztekammer (2017) Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger. URL:
13.
Zurück zum Zitat Krantz M J, Lewkowiez L, Hays H, Woodroffe M A, Robertson A D, Mehler P S. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4 Krantz M J, Lewkowiez L, Hays H, Woodroffe M A, Robertson A D, Mehler P S. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4
14.
Zurück zum Zitat Treece J M, Al Madani M, El Khoury G, Khraisha O, Martin J E, Baumrucker S J et al. Comprehensive review on methadone-induced QT prolongation and torsades. J Pharmacol Pharmacother 2018;9:66-75 Treece J M, Al Madani M, El Khoury G, Khraisha O, Martin J E, Baumrucker S J et al. Comprehensive review on methadone-induced QT prolongation and torsades. J Pharmacol Pharmacother 2018;9:66-75
15.
Zurück zum Zitat Wedam E F, Bigelow GE, Johnson RE, Nuzzo PA, Haigney M C P. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-75 Wedam E F, Bigelow GE, Johnson RE, Nuzzo PA, Haigney M C P. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-75
16.
Zurück zum Zitat Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmalogy Review: Update on Transmucosal and Long-Acting Formulations. J Addict Med 2019; in press Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmalogy Review: Update on Transmucosal and Long-Acting Formulations. J Addict Med 2019; in press
17.
Zurück zum Zitat Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012;31:8-18 Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012;31:8-18
18.
Zurück zum Zitat Greenwald MK et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9 Greenwald MK et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9
19.
Zurück zum Zitat Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 2014;144:1-11 Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 2014;144:1-11
20.
Zurück zum Zitat Bell J, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009a;104:73-7 Bell J, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009a;104:73-7
21.
Zurück zum Zitat Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study. Lancet Psychiatry 2015;2:901-8 Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study. Lancet Psychiatry 2015;2:901-8
22.
Zurück zum Zitat Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009b;104:1193-200 Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009b;104:1193-200
23.
Zurück zum Zitat Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 35:22-35 Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 35:22-35
24.
Zurück zum Zitat Hser YI et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:8-18 Hser YI et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:8-18
25.
Zurück zum Zitat Hser YI et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2016;111:695-705 Hser YI et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2016;111:695-705
26.
Zurück zum Zitat Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001;358:1417-23 Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001;358:1417-23
27.
Zurück zum Zitat Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schecter M et al. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine prescribing as treatment for refractory heroin addiction. Br J Psychiatry 2015;207:5-14 Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schecter M et al. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine prescribing as treatment for refractory heroin addiction. Br J Psychiatry 2015;207:5-14
28.
Zurück zum Zitat Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 2017;34:560-75 Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 2017;34:560-75
29.
Zurück zum Zitat Haasen C, Linden M, Tiberg F. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 2017;78:22-9 Haasen C, Linden M, Tiberg F. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 2017;78:22-9
30.
Zurück zum Zitat Walsh SL et al. Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psych 2017;74:894-902 Walsh SL et al. Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psych 2017;74:894-902
31.
Zurück zum Zitat Frost M, Bailey GL, Lintzeris et al. Longtime safety of weekly and monthly subcutanious Buprenorphindepot (CAM 2038) in the treatment of adult out-patients with Opiod Use disorders. Addiction 2019;114:1416-26 Frost M, Bailey GL, Lintzeris et al. Longtime safety of weekly and monthly subcutanious Buprenorphindepot (CAM 2038) in the treatment of adult out-patients with Opiod Use disorders. Addiction 2019;114:1416-26
32.
Zurück zum Zitat Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the treatment of Opioid Use Disorder. J Clin Pharmacol 2016;56:806-15 Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the treatment of Opioid Use Disorder. J Clin Pharmacol 2016;56:806-15
33.
Zurück zum Zitat Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 2014;53:813-24 Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 2014;53:813-24
34.
Zurück zum Zitat Nasser AF et al. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects with Opioid Use Disorder. J Clin Psychopharmacol 2016;36:18-26 Nasser AF et al. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects with Opioid Use Disorder. J Clin Psychopharmacol 2016;36:18-26
35.
Zurück zum Zitat Haight BR et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393(10173):778-90. doi: 10.1016/S0140-6736(18)32259-1 Haight BR et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393(10173):778-90. doi: 10.1016/S0140-6736(18)32259-1
36.
Zurück zum Zitat Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA. Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on ct interval during treatment for opioid use disorder. Clin Pharmacol Ther 2019;106:576-84 Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA. Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on ct interval during treatment for opioid use disorder. Clin Pharmacol Ther 2019;106:576-84
37.
Zurück zum Zitat Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A. Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 2017;7:119-34. doi: 10.1177/2045125316681984. PMID: 28348732 Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A. Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 2017;7:119-34. doi: 10.1177/2045125316681984. PMID: 28348732
38.
Zurück zum Zitat Rosenthal RN et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 2013;108:2141-9 Rosenthal RN et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 2013;108:2141-9
39.
Zurück zum Zitat Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 2016;316:282-90 Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 2016;316:282-90
40.
Zurück zum Zitat White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009;103:37-43. doi: 10.1016/j.drugalcdep.2009.03.008. PubMed PMID: 19403243 White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009;103:37-43. doi: 10.1016/j.drugalcdep.2009.03.008. PubMed PMID: 19403243
41.
Zurück zum Zitat FDA, US Food and Drug Administration (2016) Probuphine™ prescribing information. [Zugriff online 25.5.2020] FDA, US Food and Drug Administration (2016) Probuphine™ prescribing information. [Zugriff online 25.5.2020]
42.
Zurück zum Zitat Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H-U. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample. Eur Addict Res 2017;23(2):97-105 Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H-U. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample. Eur Addict Res 2017;23(2):97-105
43.
Zurück zum Zitat Bühring J. Opioidabhängige Menschen in Haft. Am unteren Ende der Hierarchie. Dt. Ärzteblätt 2019;116:1786-7 Bühring J. Opioidabhängige Menschen in Haft. Am unteren Ende der Hierarchie. Dt. Ärzteblätt 2019;116:1786-7
Metadaten
Titel
Neue Therapieoptionen in der Substitutionsbehandlung
Opiatabhängigkeit
verfasst von
Prof. Dr. Michael Soyka
Publikationsdatum
16.12.2020
Verlag
Springer Medizin
Erschienen in
CME / Ausgabe 12/2020
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-020-8112-8

Weitere Artikel der Ausgabe 12/2020

CME 12/2020 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.